HCPLive Network

Appropriate Use Criteria Established for Amyloid PET

TUESDAY, Jan. 29 (HealthDay News) -- Experts have agreed upon appropriate use criteria for positron emission tomography (PET) of brain amyloid β, according to a report published online Jan. 28 in Alzheimer's & Dementia.

Keith A. Johnson, M.D., from Massachusetts General Hospital in Boston, and colleagues, together with the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging, convened the Amyloid Imaging Task Force to provide guidance to dementia care practitioners, patients, and caregivers. Peer-reviewed, published literature was reviewed to develop a consensus opinion about the use of amyloid PET in specific clinical scenarios.

The researchers developed and agreed upon a series of specific appropriate use criteria to define the patients and clinical circumstances in which amyloid PET could be used. Amyloid imaging is appropriate when the following criteria are met: there is evidence of a cognitive complaint with objectively confirmed impairment; when Alzheimer's disease is a possible diagnosis, but that diagnosis is uncertain after a comprehensive evaluation by an expert; and when knowledge of amyloid pathology is likely to increase diagnostic certainty and alter management.

"Because both dementia care and amyloid PET technology are in active development, these appropriate use criteria will require periodic reassessment," the authors write. "Future research directions are also outlined, including diagnostic utility and patient-centered outcomes."

Multiple Task Force members and reviewers disclosed financial ties to pharmaceutical and other health care companies.

Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Positron emission tomography imaging may be used in conjunction with examinations to assess long-term outcomes in patients in a vegetative state, according to a study published online April 16 in The Lancet.
Elevated cerebral β-amyloid load is associated with greater decline in episodic and working memory for healthy and cognitively normal older adults over an 18-month period, with a larger effect than that seen for the APOE ε4 allele, according to research published in the Oct. 16 issue of Neurology.
For elderly patients, vascular brain injury is associated with lower cognitive performance, according to a study published online Feb. 11 in JAMA Neurology.
Patients who are free of dementia but have 2 parents with late-onset Alzheimer’s disease may show signs of the disease in brain scans several years, if not decades, before they display clinical symptoms.
Apparently normal older individuals with brain deposits of amyloid beta also show changes in brain structure similar to those seen in Alzheimer's patients.
Older African-Americans may be disproportionately burdened by Alzheimer's disease, according to a study published in the April issue of Health Affairs.
Current published evidence is lacking and further research is needed to establish an effect of statins on cognitive function, according to a review published in the Nov. 19 issue of the Annals of Internal Medicine.
More Reading